 Phase III trial involving topical application, in both eyes, of trabodenoson ophthalmic formulation 3.0 or 6.0 once per day or 4.5 twice per day, placebo twice per day, or timolol 0.5 twice per day for 12 weeks in adult subjects with Ocular Hypertension or Primary Open-Angle Glaucoma. 